LOX and hepatocellular carcinoma: To validate these findings in vivo, we established orthotopic HCC xenografts in C57BL/6 mice and systemically administered a monoclonal lysyl oxidase (LOX)-neutralizing antibody targeting extracellular LOX activity (Fig. 2D).